Humana Inc. (HUM)
| Market Cap | 46.23B +49.8% |
| Revenue (ttm) | 145.68B +18.3% |
| Net Income | 1.28B -18.8% |
| EPS | 10.59 -18.8% |
| Shares Out | 120.08M |
| PE Ratio | 36.36 |
| Forward PE | 31.22 |
| Dividend | $3.54 (0.92%) |
| Ex-Dividend Date | Jun 26, 2026 |
| Volume | 1,405,093 |
| Open | 364.00 |
| Previous Close | 367.24 |
| Day's Range | 363.78 - 385.66 |
| 52-Week Range | 163.11 - 428.88 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 413.09 (+7.3%) |
| Earnings Date | Jul 29, 2026 |
About HUM
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and... [Read more]
Financial Performance
In 2025, Humana's revenue was $129.66 billion, an increase of 10.11% compared to the previous year's $117.76 billion. Earnings were $1.19 billion, a decrease of -1.57%.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for HUM stock is "Buy." The 12-month stock price target is $413.09, which is an increase of 7.30% from the latest price.
News
Humana’s iCare selected for Family Care, Family Care Partnership in Wisconsin
Independent Care Health Plan, a Humana (HUM) subsidiary, has been selected by the Wisconsin Department of Health Services to serve both the Family Care and Family Care Partnership programs in…
Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin.
Morgan Stanley upgrades Humana to Equal Weight on better cost trends
Morgan Stanley analyst Erin Wright upgraded Humana (HUM) to Equal Weight from Underweight with a price target of $370, up from $249. The firm cites improving visibility into Medicare Advantage…
Humana upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Humana (HUM) to Equal Weight from Underweight with a price target of $370, up from $249.
Humana Community Day 2026 Mobilizes Thousands of Employees Nationwide to Support Healthier Communities
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced Humana Community Day 2026, its annual nationwide day of service taking place Wednesday, Aug. 26, 2026, mobilizing thousands of...
Humana price target raised to $370 from $350 at TD Cowen
TD Cowen analyst Ryan Langston raised the firm’s price target on Humana (HUM) to $370 from $350 and keeps a Hold rating on the shares. The firm said while a…
Humana price target raised to $407 from $344 at Barclays
Barclays raised the firm’s price target on Humana (HUM) to $407 from $344 and keeps an Equal Weight rating on the shares.
Piper upgrades Humana to Overweight on enterprise earnings growth
Piper Sandler upgraded Humana (HUM) to Overweight from Neutral with a price target of $463, up from $254. The stock in early trading is down 1% to $362.77. Instead of…
Humana upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler analyst Jessica Tassan upgraded Humana (HUM) to Overweight from Neutral with a price target of $463, up from $254.
Humana upgraded, Las Vegas Sands downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Humana price target raised to $405 from $320 at UBS
UBS raised the firm’s price target on Humana (HUM) to $405 from $320 and keeps a Neutral rating on the shares.
Humana upgraded to Outperform from Market Perform at Leerink
Leerink analyst Whit Mayo upgraded Humana (HUM) to Outperform from Market Perform with a $513 price target Looking at probable earnings power scenarios for 2028, the firm contends that the…
Humana price target lowered to $436 from $441 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Humana (HUM) to $436 from $441 and keeps a Buy rating on the shares. The company reported a solid Q2 beat and…
Humana price target raised to $405 from $340 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on Humana (HUM) to $405 from $340 and keeps an Outperform rating on the shares following the company’s earnings report. Overall,…
Humana price target raised to $390 from $205 at Baird
Baird raised the firm’s price target on Humana (HUM) to $390 from $205 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results where…
Humana price target raised to $471 from $269 at Guggenheim
Guggenheim raised the firm’s price target on Humana (HUM) to $471 from $269 and keeps a Buy rating on the shares, rolling forward the firm’s same target multiple onto its…
Humana downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst John Ransom downgraded Humana (HUM) to Market Perform from Outperform without a price target The Star ratings announcements over the next two months create a “binary event,”…
Evercore upgrades Humana to Outperform on improved outlook
As previously reported, Evercore ISI upgraded Humana (HUM) to Outperform from In Line with a price target of $480, up from $430, post the company’s Q2 results. Through a combination…
Humana upgraded to Outperform from In Line at Evercore ISI
Evercore ISI upgraded Humana (HUM) to Outperform from In Line with a price target of $480, up from $430.
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humana tops quarterly estimates, maintains profit outlook as medical costs stay in line
Humana reported second-quarter results that topped estimates, as the health insurer's spending on medical services came in line with expectations. The company also maintained its 2026 adjusted profit...
Humana Earnings Call Transcript: Q2 2026
Performance is on track with expectations, supported by cost control, margin expansion, and operational improvements. Stars program progress and value-based care are driving quality and financial results, while strategic divestitures and capital initiatives enhance flexibility.
Humana Earnings release: Q2 2026
Humana released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Humana Quarterly report: Q2 2026
Humana has published its Q2 2026 quarterly earnings report on July 29, 2026.
Humana Profits Hit $694 Million As Medicare Costs Fall In Line
Humana reported second quarter net income of $694 million as costs of care for older adults in its Medicare Advantage plans fell in line with company expectations.